• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Comparison of continuous infusion and bolus administration of ifosfamide in children.

作者信息

Boddy A V, Yule S M, Wyllie R, Price L, Pearson A D, Idle J R

机构信息

Cancer Research Unit, Medical School, University of Newcastle upon Tyne, U.K.

出版信息

Eur J Cancer. 1995;31A(5):785-90. doi: 10.1016/0959-8049(95)00090-6.

DOI:10.1016/0959-8049(95)00090-6
PMID:7640054
Abstract

The pharmacological effects of ifosfamide (IFO) are dependent on its metabolism which may vary between different modes of administration. This was studied in 17 patients who received both a continuous infusion (9 g/m2 over 72 h) and repeated bolus administration (3 g/m2 every 24 h for 3 days). Concentrations of IFO and its metabolites were determined in plasma and urine. There was up to 70% less of the dechloroethylated metabolites in plasma following bolus administration compared to continuous infusion. Since dechloroethylation results in the formation of the toxic metabolite chloroacetaldehyde, this difference in metabolism may have an impact on the toxicity of IFO. There were no other consistent differences between the two modes of administration. Auto-induction of IFO metabolism, with an increase in dechloroethylated metabolites, was observed for both modes of administration. In conclusion, apart from dechloroethylation, there is little difference between these two modes of administration. However, during multiple cycles of IFO therapy such differences could have a significant effect.

摘要

相似文献

1
Comparison of continuous infusion and bolus administration of ifosfamide in children.
Eur J Cancer. 1995;31A(5):785-90. doi: 10.1016/0959-8049(95)00090-6.
2
Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.异环磷酰胺肾毒性:儿科重复治疗期间代谢及给药方式的影响有限
Eur J Cancer. 1996 Jun;32A(7):1179-84. doi: 10.1016/0959-8049(96)00019-6.
3
Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration.
Cancer Chemother Pharmacol. 1996;38(2):147-54. doi: 10.1007/s002800050463.
4
Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
Cancer Res. 1993 Aug 15;53(16):3758-64.
5
Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.异环磷酰胺侧链代谢产物在持续和短期输注儿童中的排泄动力学
Int J Clin Pharmacol Ther. 1998 May;36(5):246-52.
6
The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.
Cancer Chemother Pharmacol. 1995;36(1):53-60. doi: 10.1007/BF00685732.
7
[Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols].
Klin Padiatr. 1992 Jul-Aug;204(4):299-305. doi: 10.1055/s-2007-1025364.
8
Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients.皮下注射异环磷酰胺的生物利用度及癌症患者门诊持续用药的可行性。
Ann Oncol. 1990 Sep;1(5):365-8. doi: 10.1093/oxfordjournals.annonc.a057775.
9
Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.人细胞色素P450及其常见多态性对异环磷酰胺和氘代异环磷酰胺的羟基化和N-脱氯乙基化作用
Drug Metab Dispos. 2015 Jul;43(7):1084-90. doi: 10.1124/dmd.115.063628. Epub 2015 May 1.
10
Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.门诊癌症患者皮下持续输注异环磷酰胺和环磷酰胺:生物利用度与可行性
J Cancer Res Clin Oncol. 1991;117 Suppl 4(Suppl 4):S129-34. doi: 10.1007/BF01613217.

引用本文的文献

1
Prolonged 14-day continuous infusion of high-dose ifosfamide for patients with relapsed and refractory high-grade osteosarcoma: a retrospective multicentre cohort study.大剂量异环磷酰胺 14 天持续输注治疗复发/难治性高级别骨肉瘤患者:一项回顾性多中心队列研究。
BMC Cancer. 2024 Jun 19;24(1):747. doi: 10.1186/s12885-024-12498-x.
2
Renal toxicity of ifosfamide in children with cancer: an exploratory study integrating aldehyde dehydrogenase enzymatic activity data and a wide-array urinary metabolomics approach.儿童癌症患者异环磷酰胺的肾毒性:整合醛脱氢酶酶活性数据和广泛的尿液代谢组学方法的探索性研究。
BMC Pediatr. 2024 Mar 19;24(1):196. doi: 10.1186/s12887-024-04633-1.
3
Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients.
小儿肿瘤患者中长春新碱的群体药代动力学与输注持续时间及周围神经病变的关系
Cancers (Basel). 2020 Jul 4;12(7):1789. doi: 10.3390/cancers12071789.
4
Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.基于 UPLC-ESI-QTOFMS 的代谢组学研究在小鼠体内环磷酰胺和异环磷酰胺的比较代谢。
Biochem Pharmacol. 2010 Oct 1;80(7):1063-74. doi: 10.1016/j.bcp.2010.06.002. Epub 2010 Jun 10.
5
Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.异环磷酰胺的药代动力学和代谢与通过彗星试验评估的癌症患儿DNA损伤的关系。
Br J Cancer. 2005 May 9;92(9):1626-35. doi: 10.1038/sj.bjc.6602554.
6
Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.异环磷酰胺及其脱氯乙基化和羟基化代谢产物在恶性疾病儿童中的群体药代动力学:一种稀疏采样方法。
Clin Pharmacokinet. 2001;40(8):615-25. doi: 10.2165/00003088-200140080-00005.
7
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.异环磷酰胺及其代谢产物的临床药代动力学和药效学
Clin Pharmacokinet. 2001 Jan;40(1):41-62. doi: 10.2165/00003088-200140010-00004.
8
Metabolism and pharmacokinetics of oxazaphosphorines.恶唑磷类化合物的代谢与药代动力学
Clin Pharmacokinet. 2000 Apr;38(4):291-304. doi: 10.2165/00003088-200038040-00001.
9
The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.大剂量推注和静脉滴注异环磷酰胺时的药代动力学和代谢:一项随机交叉研究。
Br J Cancer. 1998 Mar;77(6):978-84. doi: 10.1038/bjc.1998.161.
10
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.在晚期难治性恶性肿瘤中,高剂量异环磷酰胺与骨髓生长因子联合进行6天持续输注。
J Cancer Res Clin Oncol. 1997;123(4):227-31. doi: 10.1007/BF01240320.